IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)

Phase II clinical trials revealed that the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath-1H) is highly effective in the treatment of early relapsing-remitting multiple sclerosis. However, 30% of patients develop autoimmunity months to years after pulsed exposure to alemtuzu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Jones, Joanne L., Phuah, Chia-Ling, Cox, Amanda L., Thompson, Sara A., Ban, Maria, Shawcross, Jacqueline, Walton, Amie, Sawcer, Stephen J., Compston, Alastair, Coles, Alasdair J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2009
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2701868/
https://ncbi.nlm.nih.gov/pubmed/19546505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI37878
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados